This trial is active, not recruiting.

Conditions hemodialysis, malnutrition
Sponsor University of Shizuoka
Collaborator Maruyama Memorial General Hospital
Start date March 2001
End date March 2006
Trial size 300 participants
Trial identifier NCT00309426, CT2006003


The purpose of this study is to examined the effect of fetuin A on atherosclerosis and prognosis in hemodialysis patients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model defined population
Time perspective longitudinal

Eligibility Criteria

Male or female participants up to 70 years old.

Inclusion Criteria: - Hemodialysis for at least 6 months Exclusion Criteria: - Disabled patients

Additional Information

Official title The Effect of Serum Fetuin A Concentration on the 5-Year Prognosis in Hemodialysis Patients
Description Fetuin A is known to be a potent inhibitor of ectopic calcification in plasma, and the concentration of fetuin A is closely associated with protein nutritional status. The purpose of this study is to examine whether the plasma concentration of fetuin A is associated with atherosclerosis and 5-year prognosis in hemodialysis patients.
Trial information was received from ClinicalTrials.gov and was last updated in May 2006.
Information provided to ClinicalTrials.gov by University of Shizuoka.